Results of Observational Study and Integration of Epinastine 0,05% in Treatment Algorythms of Patients with Seasonal Allergic Conjunctivitis
Objective. To assess tolerability and the time of onset of clinical effect of dual-action antihistamine agents — Epinepta® (epinastine 0.05 %) and olopatadine 0.1 % in patients with seasonal allergic conjunctivitis (SAC).Subjects and methods. This was a prospective multicenter observational study....
Saved in:
Main Authors: | D. Yu. Maychuk, E. A. Drozdova, A. A. Tarkhanova, E. E. Zinych |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ophthalmology Publishing Group
2024-06-01
|
Series: | Oftalʹmologiâ |
Subjects: | |
Online Access: | https://www.ophthalmojournal.com/opht/article/view/2377 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases
by: E. V. Yani
Published: (2023-12-01) -
Use of artificial tears in cases of allergic conjunctivitis
by: D. Yu. Maycuk, et al.
Published: (2014-07-01) -
Modern opportunities of therapeutic treatment of allergic conjunctivitis. A review
by: D. Yu. Maychuk
Published: (2014-07-01) -
ALLERGIC EYE DISEASES IN CHILDREN. MODERN VIEW ON PATHOGENESIS AND TREATMENT
by: E. Y. Markova, et al.
Published: (2017-07-01) -
Our Experience Olopatadine Treatment of Allergic Conjunctivitis in Children
by: T. N. Vorontsova, et al.
Published: (2021-07-01)